The latest biotech news

News and Trends 9 Feb 2023

TILT Biotherapeutics closes €22M financing for oncology immunotherapy trials

TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, has closed its €22 million ($23.8 million) round. This follows on from the first close of €10 million in June 2022. The financing was led by Finland’s Lifeline Ventures, an early-stage venture capital firm founded by serial entrepreneurs. The funding will be used to advance […]

February 9, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 9 Feb 2023

First toxic shock syndrome vaccine phase 2 study completed

The first vaccine to potentially prevent Staphylococcal-induced toxic shock syndrome (TSS) has successfully completed a phase 2 study. TSS is a life-threatening condition caused by toxins that can lead to multiple organ failure and death. Nosocomial pathogen methicillin-resistant Staphylococcus aureus (MRSA) bacteria are resistant to widely-used antibiotics. Infections with MRSA are harder to treat and […]

February 9, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 9 Feb 2023

Cleveland Clinic breast cancer vaccine study moves forward

Researchers from global health system Cleveland Clinic have launched the next step in their novel study of a vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease. Funded by the U.S. Department of Defense, the new phase 1b study will enroll cancer-free individuals at high risk for developing […]

February 9, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 7 Feb 2023

Antibody candidate for treating serious liver disease

There is currently no drug for treating non-alcoholic fatty liver disease, which affects many people with type 2 diabetes and which can result in other serious liver diseases. However, a new study led by researchers from Karolinska Institutet in Sweden has identified a drug candidate for the treatment of fatty liver. The preclinical study, published […]

February 7, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 7 Feb 2023

Evonetix closes $24M financing

Evonetix Ltd, a synthetic biology company bringing semiconductor technology to DNA synthesis, has completed a $24 million financing round, extending its total series B funding to over $54 million. This fundraise was led by existing investor Foresite Capital, with Molten Ventures, Morningside, DCVC, Cambridge Consultants, Civilization Ventures and Providence also participating in the round. The […]

February 7, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 7 Feb 2023

Harvard spin-off cellvie closes $5.5M new funding

cellvie Inc., which works on therapeutic mitochondria transplantation (TMT), an approach developed at Harvard Medical School, has closed a $5.5 million financing to get Series A-ready by the end of 2023. Mitochondria dysfunction has been tied to a host of diseases, ranging from neurodegenerative ailments, heart attacks and strokes, to age-related degeneration. “Whilst mitochondria have […]

February 7, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 7 Feb 2023

Mnemo Therapeutics and Institut Curie studies lead to cancer-specific targets

Mnemo Therapeutics, a French biotechnology company developing immunotherapies, has announced publication of two scientific studies developed at Institut Curie, its closest academic collaborator, in the journal Science Immunology. The publications reveal TE-exon splicing junctions act as a source of novel recurrent, cancer-specific targets and have potential implications for developing more effective and less toxic immunotherapies. […]

February 7, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 7 Feb 2023

Certa scleroderma study shows improvement in more than 60% of patients

Certa Therapeutics has announced what it says are ground-breaking clinical trial data for FT011, its novel therapy for the treatment of serious inflammatory and fibrotic diseases. Certa Therapeutics has recently completed a global phase 2, multi-centre, randomized, double blind, placebo-controlled study of the pharmacokinetics, pharmacodynamic effects, and safety, of oral FT011 in patients with scleroderma. […]

February 7, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 7 Feb 2023

AAHI bags $9.9M to develop nasal spray influenza RNA vaccine

The Access to Advanced Health Institute (AAHI) has been awarded a project agreement worth up to $9.9 million through the Medical CBRN Defense Consortium (MCDC) Other Transaction Authority (OTA) to develop a prototype intranasal bivalent influenza RNA vaccine candidate. The candidate will be based on AAHI’s self-amplifying RNA (saRNA) platform, which targets both pandemic A(H5N1) […]

February 7, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 7 Feb 2023

Endogena Therapeutics retinitis pigmentosa treatment gets FDA fast track designation

The US Food and Drug Administration (FDA) has designated the investigation of Endogena Therapeutics’ EA-2353 for the treatment of retinitis pigmentosa (RP) as a fast track development program. Fast track is a process designed to enable patients to benefit earlier from new drugs for serious conditions. Endogena Therapeutics’ EA-2353 takes a novel, small-molecule approach and […]

February 7, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 3 Feb 2023

Beyond Biotech podcast 32: Cancer Research Horizons, Enterome, OncoHost, TrakCel, Turbine

Our guests are Ofer Sharon, CEO of OncoHost; Matthew Lakelin, co-founder, TrakCel; Pierre Belichard, CEO of Enterome; and Tony Hickson, chief business officer for Cancer Research UK and Cancer Research Horizons and Daniel Veres, chief science officer and co-founder, Turbine. World Cancer Day February 4 is World Cancer Day. This year, the theme is Close […]

February 3, 2023

News and Trends 3 Feb 2023

UK approval for AbbVie Crohn’s disease drug

AbbVie has announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved RINVOQ (upadacitinib), a janus kinase (JAK) inhibitor, for the treatment of adult patients with moderately to severely active Crohn’s disease (CD) who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biological agent. […]

February 3, 2023 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

TILT Biotherapeutics closes €22M financing for oncology immunotherapy trials

First toxic shock syndrome vaccine phase 2 study completed

Cleveland Clinic breast cancer vaccine study moves forward

Antibody candidate for treating serious liver disease

Evonetix closes $24M financing

Harvard spin-off cellvie closes $5.5M new funding

Mnemo Therapeutics and Institut Curie studies lead to cancer-specific targets

Certa scleroderma study shows improvement in more than 60% of patients

AAHI bags $9.9M to develop nasal spray influenza RNA vaccine

Endogena Therapeutics retinitis pigmentosa treatment gets FDA fast track designation

Beyond Biotech podcast 32: Cancer Research Horizons, Enterome, OncoHost, TrakCel, Turbine

UK approval for AbbVie Crohn’s disease drug

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!